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Protease activated receptors (PAR) have been shown to play a role in inﬂammation. PAR-2 is expressed by numerous cells in the
lung and has either proinﬂammatory, anti-inﬂammatory, or no eﬀect depending on the model. Here, we examined the role of
PAR-2 in a model of LPS-induced lung inﬂammation. We found that PAR-2-deﬁcient mice had signiﬁcantly less KC expression in
bronchial lavage ﬂuid compared with wild-type mice but there was no diﬀerence in MIP-2 or TNF-α expression. We also found
that isolated alveolar and resident peritoneal macrophages lacking PAR-2 showed a similar deﬁcit in KC after LPS stimulation
without diﬀerences in MIP-2 or TNF-α. Inﬁltration of neutrophils and macrophages into the lung following LPS administration
was notaﬀected byan absence of PAR-2.Our resultssupportthenotion that PAR-2plays aroleinLPSactivation of TLR4signaling
in macrophages.
1.Introduction
The protease activated receptors (PAR) are a four-member
familyof7transmembraneG-protein-coupledreceptorsthat
are activated by cleavage of an amino terminal sequence
resulting in exposure of a tethered ligand. PARs act as
sensors of both coagulation and noncoagulation proteases,
including thrombin, trypsin, and mast cell tryptase. It is
thought that PARs act as a major link between coagulation
and inﬂammation. PARs are expressed in many diﬀerent
cell types. In the lung, PAR-2 is expressed by epithelial cells
[1], smooth muscle cells [1], ﬁbroblasts [2], and endothelial
cells [3]. In addition, PAR-2 is expressed on a variety of
immune cells including mast cells [4], macrophages [5], and
neutrophils [6].
PAR-2 is activated by trypsin, mast cell tryptase, matrip-
tase, and the coagulation proteases Factor VIIa and Xa in
vitro [7]. However, it is unclear which proteases activate
PAR-2 in vivo [7]. Mimics of the tethered ligand, termed
PAR-2 agonist peptides (PAR-2 AP), can also induce PAR-2
signaling. Scrambled analogs to these peptides are often
used as negative controls. However, signaling initiated by
proteases and agonist peptides may not have the same results
[8].
All 4 PARs have been shown to be present in rat lungs,
and their expression is modulated after endotoxin admin-
istration [9]. The role of PAR-2 in lung inﬂammation is
controversial. PAR-2 has been found to be upregulated in the
lungfollowingexposuretoviruses,lipopolysaccharide(LPS),
tobacco smoke, and allergens [10, 11]. Two groups found
that administration of large amounts of PAR-2 AP in mouse
airways reduced cellular inﬁltration induced by LPS [12, 13].
This reduction may be related to PAR2-dependent produc-
tionofprostaglandinE2[13].However,anothergroupfound
no diﬀerences in three diﬀerent models of acute lung injury
between PAR-2-deﬁcient and wild-type mice [14]. A proin-
ﬂammatoryroleforPAR-2inthelunghasalsobeenobserved
in PAR-2-deﬁcient mice by two diﬀerent groups [15, 16].
These contradictory observations may be due to diﬀering
administration routes of the agonist peptide, the amounts2 Journal of Signal Transduction
used,andthetypeofinsult.Clearly,furtherinvestigationinto
the role of PAR-2 in lung inﬂammation is warranted.
It has been proposed that PAR-2 and the LPS receptor,
toll-like receptor 4 (TLR4) cooperate to enhance proinﬂam-
matory signaling [17]. This group found that cotransfection
of HEK293T cells with PAR-2 and TLR4 enhanced NF-κB
activation by PAR-2 AP. This eﬀect was speciﬁc to TLR4, as
TLR3 and TLR2 did not show similar enhancement [17]. It
was also noted that the TLR4-mediated enhancement was
working through the intracellular adaptor molecules TRIF
and TRAM [17]. However, more recent work by the same
group shows that stimulation of thioglycollate elicited peri-
toneal macrophages with PAR-2 AP suppressed proinﬂam-
matory cytokines and enhanced anti-inﬂammatory cytokine
production in response to LPS [18]. In addition, thioglycol-
late-elicited peritoneal macrophages from PAR-2-deﬁcient
mice were found to have a hyperinﬂammatory response to
LPS[18].Therefore,thePAR-2andTLR4signalingresponses
are likely intertwined though the exact mechanism and in
vivo relationship have yet to be elucidated.
In order to further elucidate the role of PAR-2 in LPS
induced lung inﬂammation, we subjected PAR-2-deﬁcient
and wild-type mice to intratracheal LPS administration. We
found no diﬀerence in cellular inﬁltration into the lungs. We
observed a deﬁcit in the chemokine, keratinocyte chemoat-
tractant (KC; CXCL1), in the bronchial alveolar lavage ﬂuid
(BALF) from PAR-2-deﬁcient mice. In addition, PAR-2 deﬁ-
ciency had no eﬀect on the proinﬂammatory cytokine tumor
necrosis factor-α (TNF-α), or the chemokine macrophage
inﬂammatory protein-2 (MIP-2; CXCL2) in the BALF.
However, compared to wild-type mice, MIP-2 levels were
found to be lower in lung homogenates of PAR-2-deﬁcient
mice treated with LPS. Furthermore, we found that PAR-
2-deﬁcient alveolar and resident peritoneal macrophages
produced less KC after ex vivo LPS stimulation.
2.MaterialsandMethods
2.1. Mice. The generation of PAR-2+/+ (wild-type) and PAR-
2−/− mice has been previously described [19]. Mice were
8 to 10 weeks of age at the time of experiments. All
experimental protocols were approved by the University of
North Carolina-Chapel Hill’s Institutional Animal Care and
Use Committee.
2.2. Intratracheal LPS Instillation and BALF Collection. The
method of intratracheal LPS instillation has been described
[20]. Mice were anesthetized by intraperitoneal injection of
12.5mg/mL tribromoethanol (TBE) (Acros Organics), at a
dose of 0.02mL TBE per gram of mouse body weight. LPS
from E. coli serotype O111:B4 was purchased from Sigma-
Aldrich. 10μg of LPS was instilled into the left lung of wild-
type or PAR-2 knockout mice, and animals were sacriﬁced
at indicated timepoints by diaphragmatic incision. Control
mice did not receive LPS. Lungs from treated and untreated
mice were lavaged postmortem by insertion of a 27-gauge
catheter into the exposed trachea (BD Biosciences). The
lungs were instilled three times with 900μL of phosphate
buﬀeredsaline (PBS),andtheBALFwassuctionedoutofthe
lungs after each instillation using a 1mL syringe.
2.3. Sample Preparation. BALF was prepared for ELISA
by immediate centrifugation of 1mL samples at 500×g
for 20 minutes at 4◦C, and the supernatant was frozen
and stored at −80◦C. Pelleted cells were resuspended in
200μL PBS and retained for evaluation by ﬂow cytometry.
After BALF collection, the left lung lobe was excised, snap
frozen in liquid nitrogen, and stored at −80◦Cp r i o rt o
homogenization. For protein extraction, the lungs were
thawed, weighed, and suspended in lysis buﬀer (1% SDS,
10% Glycerol, and 100mM Tris) with protease (Sigma-
Aldrich) and phosphatase inhibitors (Thermo Scientiﬁc).
One hundred μLo fl y s i sb u ﬀer per 10mg of tissue was
used. Lung tissue was ground with a homogenizer for ∼1
minute, and the samples were rested on ice for 30 minutes
before centrifugation at 4◦C, 16,000×g for 10 minutes. The
protein concentration in the samples was measured using
the DC Protein Assay from Bio-Rad Laboratories, and the
homogenate was aliquoted and frozen at −80◦C until use.
2.4. ELISA. Mouse KC, MIP-2, Lix, and TNF-α DuoSet
ELISA kits were purchased from R&D Systems.
2.5. Flow Cytometry. C e l l sw e r ec o l l e c t e df r o mB A L Fa s
described in sample preparation. Total non-red blood cells
were then enumerated using a Coulter counter (Beckman
Coulter).Cellswerestainedaspreviouslydescribed[21]with
anti-mouse F4/80 Paciﬁc Blue and anti-mouse 7/4-FITC,
both purchased from AbD Serotec (Oxford, UK).
2.6.LPSStimulationofMacrophages. F oralveolarmacropha-
ges, cells were isolated from individual mice as described
in sample preparation. Resident peritoneal macrophages
were harvested as previously described [21]. Cells were
then counted and plated in 150μL of media (DMEM-H
containing 10% FBS and Penicillin/Streptomycin) in 96 well
plates. After 3 hours, nonadherent cells were removed. The
next day cells were stimulated for indicated times with
100ng/mL of LPS.
3. Results
3.1. Mice Lacking PAR-2 Have Reduced KC Expression Follow-
ing Intratracheal LPS Instillation. In order to determine the
eﬀectsofPAR-2duringacutelunginﬂammation, weinstilled
LPS into the left lung of wild-type and PAR-2−/− mice.
We then harvested BALF and lung tissue and performed
ELISAs for the chemokines KC, MIP-2, and Lix, and the
proinﬂammatory cytokine TNF-α. As shown in Figure 1(a),
BALF collected from mice lacking PAR-2 had signiﬁcantly
reduced KC at 3 and 6 hours after LPS instillation. However,
MIP-2, TNF-α, and Lix levels in the BALF were unaﬀectedby
PAR-2 deﬁciency (Figures 1(b) and 1(c), data not shown).
Surprisingly, KC levels in lung homogenates from mice in
Figure 1(a) showed little KC induction and no diﬀerenceJournal of Signal Transduction 3
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Figure 1: Chemokine and cytokine expression in BALF and lung homogenates after intratracheal LPS instillation. 10μgo fL P S( E. coli
O111:B4) was instilled into the left lungs of wild-type (PAR2+/+, white bars) and PAR-2−/− (black bars) mice for indicated time periods.
BALF and lungs were collected, and lungs were homogenized. ELISAs on BALF were performed for KC (a), MIP-2 (b), and TNF-α (c).
ELISAs on lung homogenates were performed for KC (d), MIP-2 (e), and TNF-α (f). n ≥ 4. ∗P<0.05; ∗∗P<0.001 by two way ANOVA
posttest.
between genotypes (Figure 1(d)). A transient deﬁcit in MIP-
2 was found at 3 hours after LPS instillation in mice lacking
PAR-2, although this deﬁcit was not apparent at the 6 and
12 hour time points (Figure 1(e)). Finally, TNF-α showed
a small increase in lung homogenates 3 hours after LPS
instillation; however, no diﬀerences were observed between
genotypes (Figure 1(f)).
3.2. Alveolar and Resident Peritoneal Macrophages Lacking
PAR-2 Have Reduced KC Expression Following LPS Stimu-
lation. Since KC production was found to be dramatically
elevated in BALF compared to lung homogenates and the
P A R - 2 - d e p e n d e n tK Cd e ﬁ c i tw a so n l yo b s e r v e di nB A L F ,
we hypothesized that alveolar macrophages may be the
source of KC in the BALF. Therefore, we isolated alveolar
macrophagesfromna¨ ıvewild-typeandPAR-2-deﬁcientmice
and stimulated them with LPS for 3 hours because the
largest amount of KC in the BALF was observed 3 hours
after LPS instillation. We observed a signiﬁcant deﬁcit in
KC production by alveolar macrophages isolated from PAR-
2−/− animals compared to their wild-type counterparts
(Figure 2(a)). Similar to Figure 1, we found no signiﬁcant
diﬀerences between genotypes in MIP-2 or TNF-α levels
in alveolar macrophage cell supernatants (Figures 2(b) and
2(c)).Sinceonlyasmallnumberofalveolarmacrophagescan
be isolated, we repeated a similar experiment using resident
peritoneal macrophages stimulated with LPS for 3 and 6
hours. We observed a signiﬁcant deﬁcit in KC expression at 3
and 6 hours in cells from mice lacking PAR-2 (Figure 2(d)).
Although MIP-2 and TNF-α were dramatically increased
following LPS stimulation, we found no diﬀerences between
genotypes in MIP-2 or TNF-α expression by resident peri-
toneal macrophages (Figures 2(e) and 2(f)).
3.3. No Eﬀect on Cellular Inﬁltration to LPS Instilled Lungs
in PAR-2-Deﬁcient Mice. In order to determine if the
observed deﬁcit in KC expression in BALF and alveolar
macrophages resulted in a deﬁcit in cellular inﬁltration, we
isolated cells from the BALF following LPS instillation. We
observed neutrophil and macrophage inﬁltration by ﬂow
cytometry. We found no signiﬁcant diﬀerences in neutrophil
(Figure 3(a)), macrophage (Figure 3(b)) or total cellular
(Figure 3(c)) inﬁltration in the BALF of PAR-2−/− mice
compared to their wild-type counterparts.
4. Discussion
Here, we have presented data showing that a lack of PAR-2
leads to a deﬁcit in KC expression both in vivo and in vitro.
This deﬁcit is speciﬁc to KC as other chemokines including
MIP-2 and Lix (data not shown) were similar between geno-
types. In addition, the proinﬂammatory cytokine TNF-α is
not aﬀected by the absence of PAR-2 in vivo or in vitro.
Interestingly, we found similar levels of KC in the lung
tissue in both genotypes; in fact, little induction of KC was
observed in the lung homogenates after LPS administration.
This suggests that the cells found within the BALF, such
as alveolar macrophages, are the major source of KC in
the lung in response to intratracheal LPS stimulation. In
contrast, MIP-2 was found to be induced in both the BALF4 Journal of Signal Transduction
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Figure 2: LPS stimulation of chemokines and TNF-α in alveolar and resident peritoneal macrophages. Macrophages from wild-type
(PAR2+/+, white bars) and PAR-2−/− (black bars) mice were left untreated or stimulated with 100 ng/mL of LPS for indicated time periods.
ELISAs on cell supernatants from alveolar macrophages were performed for KC (a), MIP-2 (b), and TNF-α (c). ELISAs on cell supernatants
from resident peritoneal macrophages were performed for KC (d), MIP-2 (e), and TNF-α (f). n = 3. ∗P<0.05; ∗∗P<0.001 by two way
ANOVA posttest.
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Figure 3: Cellular inﬁltration into the lung following LPS instillation. BALF was collected from wild-type (PAR2+/+, white bars) and PAR-
2−/− (black bars) mice at indicated time periods after intratracheal LPS instillation. Neutrophils (a), macrophages (b), and total cells (c) were
enumerated by ﬂow cytometry. n ≥ 4.
and lung tissues. While MIP-2 in the BALF was induced by
LPS,nodiﬀerenceswerefoundbetweengenotypes.However,
a transient deﬁcit in MIP-2 induction was observed in the
lung homogenate of animals lacking PAR-2 3 hours after
intratracheal LPS instillation. This data suggests that cells
other than the alveolar macrophages use PAR-2 for MIP-
2 expression, though the relative contribution of alveolar
macrophagesandothercellsinthelungtoMIP-2production
is still unclear.
Although deﬁcits in KC induction in both mice and
cells lacking PAR-2 were dramatic, the biological relevance
of this pathway remains to be elucidated. It is well known
that KC is a potent chemokine that recruits neutrophils
and macrophages to sites of infection. However, we did not
observe a diﬀerence in cellular inﬁltration into the lungs
of animals lacking PAR-2, though cellular inﬁltrates signif-
icantly increased in both genotypes. It is possible that the
production of other chemokines which recruit neutrophils
and macrophages, such as MIP-2 and Lix, is suﬃcient.
We also observed a deﬁcit in KC expression in LPS-
treated resident peritoneal macrophages lacking PAR-2,
suggestingthatPAR-2signalingisrequiredforKCexpression
by macrophages in locations other than the lung. Similar
to alveolar macrophages, MIP-2 and TNF-α production
was unaﬀected by the lack of PAR-2 in resident peritoneal
macrophages. Interestingly, Peters and colleagues found that
costimulation of alveolar macrophages with LPS and PAR-2
AP showed similar induction of MIP-2 in vitro comparedJournal of Signal Transduction 5
to LPS alone [13]. Similarly, we found that PAR-2 AP was
unable to stimulate KC or MIP-2 production by alveolar
macrophages (data not shown). In addition, KC and MIP-2
production by alveolar macrophages costimulated with LPS
and PAR-2 AP was similar to stimulation with LPS alone
(data not shown). Taken together, these data suggest that
signaling via PAR-2 resulting in chemokine production may
not require PAR-2 activation.
Other groups have investigated a role for PAR-2 in lung
inﬂammation. However, the use of knockout mice has been
limited and, surprisingly, few have examined chemokine and
proinﬂammatory cytokine production. Large amounts of
PAR-2 AP have also been used to reduce cellular inﬁltration
induced by LPS administration in the lungs [12]. However,
the mechanism of this suppression was not determined and
importantly was not shown to be absent in PAR-2−/− mice.
Another group found similar reductions in cellular inﬁltra-
tion into the lung using large amounts of PAR-2 AP and
LPS coadministration compared to LPS alone. However, this
group found a deﬁcit in KC and MIP-2 in the BALF 1
hour after stimulation, although this deﬁcit was no longer
apparent after 3 hours [13]. These results are in contrast
to the ﬁndings presented in this paper; however, both of
these groups used Balb/C mice and LPS from E. coli strain
0127:B8. It is possible that mouse and LPS strain diﬀerences
contribute to this discrepancy.
Itisalsoimportanttonotethattheproteasesthatactivate
PAR-2 in the lung have not been well deﬁned. It is speculated
that mast cell tryptase is the endogenous activator of PAR-2
inthelung.However,itispossible thatother,asyetunidenti-
ﬁed, enzymes contribute to PAR-2 cleavage. In addition, the
activation of PAR-2 by the PAR-2 AP and the endogenous
tethered ligand may result in diﬀerent downstream signaling
events [8, 22]. Further investigation of the role of PAR-2 in
lung inﬂammation is critical, as blockade of PAR-2 has been
suggested as a possible therapeutic approach to reduce lung
inﬂammation. Importantly, the inhibition of PAR-2 during
chronic or allergic lung inﬂammation may have entirely
diﬀerent results from the acute lung inﬂammatory states
presented in this study.
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